A randomized, 2-arm non-comparative phase II study on the efficacy of atezolizumab and Roche bevacizumab (Atezo/Bev) followed by ondemand selective TACE (sdTACE) upon detection of disease progression or of initial synchronous treatment with TACE and Atezo/Bev on 24-months survival rate in the treatment of unresectable hepatocellular carcinoma patients

Atezolizumab (Tecentriq®), Bevacizumab (Avastin®)

Status: In Rekrutierung

Klinische Settings

Beteiligte

Identifier

Links

Kontakt